Connecticut Movers: Laterals to Two Top Firms, Plus Pro Bono Accolades Announced
Pullman & Comley and Day Pitney welcome experienced attorneys to their teams; Lawyers for Good Government announces award ...
BioPharma Dive1h
Dengue is spreading and Sanofi is pulling the US market’s only vaccine. What’s next?
As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...
Bloomberg L.P.5h
Bankers Do Anything It Takes to Grab a Slice of Rare Buyout Deal
CD&R this week entered exclusive talks with drugmaker Sanofi to buy half of its consumer arm, Opella. Getting burned on ...
Sanofi announces presentation of Dupixent Phase 3 data in CSU
Data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent in biologic-naive patients with uncontrolled chronic ...
The Pharma Letter1h
Biocon Phase III data on switching biosimilar aflibercept
Indian drugmaker Biocon subsidiary Biocon Biologicals has released a new extension study evaluating MYL-1701P, a proposed ...
The Pharma Letter1h
Kisqali gains endorsement for early breast cancer
The NCCN has updated its breast cancer guidelines, designating Novartis' Kisqali as a Category 1 preferred CDK4/6 inhibitor ...
Yahoo Finance3h
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support US regulatory resubmission by year-end; if ...